Shares of Zai Lab rose about 8% after the company announced a global clinical trial collaboration with Amgen to evaluate its investigational DLL3-targeting antibody-drug conjugate. The collaboration provides validation from a major biotech partner and could de-risk and accelerate development, but the program remains early-stage and ultimate value depends on clinical outcomes.
Shares of Zai Lab rose about 8% after the company announced a global clinical trial collaboration with Amgen to evaluate its investigational DLL3-targeting antibody-drug conjugate. The collaboration provides validation from a major biotech partner and could de-risk and accelerate development, but the program remains early-stage and ultimate value depends on clinical outcomes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
